Catto GR, MacLeod M, Pelc B, Kodicek E. I alpha-hydroxycholecalciferol: a treatment of renal bone disease.
BRITISH MEDICAL JOURNAL 1975;
1:12-4. [PMID:
1120218 PMCID:
PMC1671878 DOI:
10.1136/bmj.1.5948.12-a]
[Citation(s) in RCA: 32] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Three patients with chronic renal failure on maintenance haemodialysis have been treated with 1 alpha-hydroxycholecalciferol (1 alpha-OHCC), a synthetic vitamin D analogue. A daily dose of 2 mug by mouth produced a significant increase in both calcium absorption from the gastrointestinal tract and calcium content of bone. Treatment with 1 alpha-OHCC appears to be effective in cases of metabolic bone disease associated with chronic renal failure.
Collapse